SCHEMBL2017558

SCHEMBL2017558

COc1ccc(CN(C)c2nnc(-c3c(C)cc(C)cc3C)c3ccccc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.43
EGFR P00533 1/20 0.43
CRHR1 P34998 5/20 0.40
ALDH1A1 P00352 2/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TSPO P30536 1/20 0.38
SMPD1 P17405 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PIK3CD O00329 1/20 0.37
PIK3R2 O00459 1/20 0.37
PIK3CG P48736 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
ACP1 P24666 1/20 0.36
KEAP1 Q14145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2019715 0.89 ALDH1A1 (0.48) CSF1REGFRCRHR1ALDH1A1LMNA
SCHEMBL2016765 0.88 GABRA1 (0.46) CSF1REGFRCRHR1ALDH1A1LMNA
SCHEMBL2025924 0.83 GBA1 (0.42) CSF1RCRHR1MEN1KMT2A
SCHEMBL2021464 0.81 SMN1; SMN2 (0.49) CSF1REGFRALDH1A1LMNATSPO
SCHEMBL2019830 0.81 CSF1R (0.40) CSF1REGFRCRHR1MEN1KMT2A
SCHEMBL2020840 0.78 PYCR1 (0.35) CSF1REGFRCRHR1ALDH1A1HTT
SCHEMBL6965022 0.75 CRHR1 (0.47) CSF1RCRHR1ALDH1A1HTTNPSR1
SCHEMBL2046515 0.73 CRHR1 (0.46) CSF1REGFRCRHR1
SCHEMBL2020985 0.73 CSF1R (0.43) CSF1RLMNAHTTNPSR1MEN1
SCHEMBL2016891 0.73 DHFR (0.39) CSF1REGFRALDH1A1LMNAGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US claimed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines MMP25, MMP9, MMP3 CSF1R 1219/4885EGFR 615/4885CRHR1 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.